Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZDBNL
ADC Name
Anti-MSL1 mAb-Compound 31
Synonyms
Anti MSL1 mAb Compound 31
   Click to Show/Hide
Organization
Rongchang Pharmaceuticals Ltd.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
3.6
Antibody Name
Anti-MSL1 mAb
  Antibody Info 
Antigen Name
Male-specific lethal 1 homolog (MSL1)
  Antigen Info 
Payload Name
Auristatin 0101
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Anti-MSL1 mAb-Compound 31 linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
37.38
nM
CVCL_0465
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 37.38 nM Positive MSL expression (MSL+++/++)
Method Description
The cells were incubated in a CO2 incubat or with saturated water overnight, On the second day, two covalent thiol conjugated ADCs were serially diluted conjugates were added to the 96 well plate containing OVCAR3 cells, 100uL per well. The initial conjugate was 100000 ng/ml and diluted to 0.001 ng/ml. OVCAR3 cells with added ADC were incubated at 37 for 72 hours.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
References
Ref 1 Covalent linkers in antibody-drug conjugates and methods of making and using the same.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.